CF
FLNA

Cantor Fitzgerald’s Filana Therapeutics FLNA Stock Holding History

Cantor Fitzgerald’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-170,700
Closed -$2.84M – 494
2023
Q3 		$2.84M Buy
+170,700
New +$3.38M 0.08% 204
2023
Q2 		– Sell
-46,200
Closed -$1.11M – 639
2023
Q1 		$1.11M Buy
+46,200
New +$1.28M 0.02% 362

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TI
Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cantor Fitzgerald's FLNA Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Filana Therapeutics (FLNA) in Q4 2023, closing a stake of 170,700 shares — an estimated $2.84M sold.

Cantor Fitzgerald first reported a position in FLNA in Q1 2023 and held it in 2 quarters. The position peaked at $2.84M in Q3 2023. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2023.

  • Cantor Fitzgerald reported no remaining Filana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 170,700 Filana Therapeutics shares in Q4 2023, an estimated $2.84M.
  • Cantor Fitzgerald first reported a position in Filana Therapeutics in Q1 2023 and held it in 2 quarters.
  • Cantor Fitzgerald's Filana Therapeutics position peaked at $2.84M in Q3 2023.
  • 153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.